Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–12 of 12 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: PRT064445 Clear all
Completed No phase listed Observational

Andexanet Alfa and 4F-PCC Use in Patients Hospitalised With an Anticoagulant-related Major Bleed

NCT05548777
View directory record Official record
Conditions
Anticoagulant-related Major Bleed
Interventions
Andexanet alfa, 4F-PCC
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
5,480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Agoura Hills, California
Source: ClinicalTrials.gov public record
Updated Nov 27, 2023 · Synced Sep 2, 2026, 5:01 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

A Healthy Volunteer PK/PD, Safety and Tolerability Study of Andexanet After Betrixaban Dosing

NCT03330457
View directory record Official record
Conditions
Bleeding
Interventions
Andexanet alfa (bolus), Betrixaban 80 mg PO QD, Andexanet alfa (infusion IV)
Biological · Drug
Lead sponsor
Portola Pharmaceuticals
Industry
Eligibility
18 Years to 45 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Aug 7, 2023 · Synced Sep 2, 2026, 5:01 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects

NCT03310021
View directory record Official record
Conditions
Bleeding
Interventions
Andexanet alfa, Apixaban, Rivaroxaban, Edoxaban, Placebo
Biological · Drug
Lead sponsor
Portola Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Sep 2, 2026, 5:01 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study in Older Subjects to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Apixaban

NCT02207725
View directory record Official record
Conditions
Bleeding
Interventions
Andexanet, Placebo
Biological · Other
Lead sponsor
Portola Pharmaceuticals
Industry
Eligibility
50 Years to 75 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 7, 2023 · Synced Sep 2, 2026, 5:01 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 1 of 4)

NCT01758432
View directory record Official record
Conditions
Healthy Volunteers
Interventions
PRT064445/Apixaban, Placebo/Apixaban, Placebo
Combination Product · Drug
Lead sponsor
Portola Pharmaceuticals
Industry
Eligibility
18 Years to 45 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 6, 2023 · Synced Sep 2, 2026, 5:01 PM EDT
Terminated Phase 2 Interventional Results available

Trial of Andexanet in Patients Receiving an Oral FXa Inhibitor Who Require Urgent Surgery

NCT04233073
View directory record Official record
Conditions
Surgery
Interventions
andexanet alfa
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 84 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
20
States / cities
Phoenix, Arizona • Tucson, Arizona • Long Beach, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Sep 2, 2026, 5:01 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study in Older Subject to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Rivaroxaban

NCT02220725
View directory record Official record
Conditions
Bleeding
Interventions
Andexanet, Placebo
Biological · Other
Lead sponsor
Portola Pharmaceuticals
Industry
Eligibility
50 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Sep 2, 2026, 5:01 PM EDT
Completed Phase 3 Interventional Results available

A Study in Participants With Acute Major Bleeding to Evaluate the Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Direct and Indirect Oral Anticoagulants (Extension Study)

NCT02329327
View directory record Official record
Conditions
Bleeding
Interventions
Andexanet
Biological
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
479 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
23
States / cities
Long Beach, California • Los Angeles, California • Orange, California + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2022 · Synced Sep 2, 2026, 5:01 PM EDT
Completed Phase 4 Interventional Results available

Trial of Andexanet Alfa in ICrH Patients Receiving an Oral FXa Inhibitor

NCT03661528
View directory record Official record
Conditions
Acute Intracranial Hemorrhage
Interventions
andexanet alfa, Usual Care
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
11
States / cities
Fort Lauderdale, Florida • Augusta, Georgia • Royal Oak, Michigan + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Sep 2, 2026, 5:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Healthy Volunteer PK/PD, Safety and Tolerability Study of Second Generation Andexanet Alfa

NCT03083704
View directory record Official record
Conditions
Bleeding
Interventions
Andexanet alfa (Gen 1 Process 2), Apixaban 5 MG, Rivaroxaban 20 MG, Enoxaparin sodium, Edoxaban 60 MG, Andexanet alfa (Gen 2), Andexanet alfa (Gen 1 Process 3), Apixaban 10 MG, Rivaroxaban 10 MG
Biological · Drug
Lead sponsor
Portola Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Aug 7, 2023 · Synced Sep 2, 2026, 5:01 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 3 of 4)

NCT03551730
View directory record Official record
Conditions
Healthy Volunteers
Interventions
PRT064445/Enoxaparin, Placebo/Enoxaparin, Placebo
Combination Product · Drug
Lead sponsor
Portola Pharmaceuticals
Industry
Eligibility
18 Years to 45 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Sep 2, 2026, 5:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose Study of PRT064445, a Factor Xa (fXa) Inhibitor Antidote

NCT03218241
View directory record Official record
Conditions
Healthy
Interventions
PRT064445, Placebo
Biological · Drug
Lead sponsor
Portola Pharmaceuticals
Industry
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 3, 2023 · Synced Sep 2, 2026, 5:01 PM EDT